AL Slobodyanuk, ID Shipunov, KV Sineva and VI Kupaev*

Samara State Medical University, Russian Federation, Russia

*Corresponding Author: VI Kupaev, Samara State Medical University, Russian Federation, Russia.

Received: February 01, 2022; Published: May 11, 2022

Abstract

Aim of the Study: To analyze pharmacotherapy of essential hypertension in patients, who have achieved a controlled course of the disease.

Materials and Methods: In this study 274 patients with controlled course of stage 2 arterial hypertension and no comorbidities were recruited. Blood pressure indicators, the volume of drug therapy for hypertension were analyzed.

Results: The study included 543 drug prescriptions. In 97 (35.3%) patients only one drug was prescribed, in 112 (40.7%) - two drugs, in 46 (16.7%) - three drugs from various pharmacological groups, among which monodrugs were in the lead: angiotensin-converting-enzyme inhibitors (ACE-inhibitors) - 31.86%, cardioselective β-blockers - 23%, angiotensin 2 receptor blockers - 9.3%. Combined drugs were present in 18.4% of general doctors` prescriptions.

Conclusion: Pharmacotherapy in patients with stage 2 essential hypertension, belonging to the group of high risk of cardiovascular complications, does not fully comply with modern clinical recommendations in general medical practice.

Keywords: Essential Hypertension; Arterial Hypertension; Pharmacological Therapy

References

1. Massimo F Piepoli., et al. “2016 European Guidelines on cardiovascular disease prevention in clinical practice”. European Heart Journal29 (2016): 2315-2381.
2. Suzanne Oparil., et al. “Hypertension”. Nature Reviews Disease Primers (2019).
3. Oschepkova EV. “Five-year results of realization of federal target program “Prevention and treatment of arterial hypertension in Russian Federation (2002-2006)”. Therapeutic Archives9 (2007): 25-30.
4. Evstifeeva SE., et al. “Evaluation of treatment and prevention among patients with arterial hypertension in primary care unit (data from hypertension register)”. Atmosphere Cardiologiya 4 (2007): 18-20.
5. Estruch R., et al. “Primary prevention of cardiovascular disease with a Mediterranean diet”. The New England Journal of Medicine14 (2013): 1279-1290.
6. Rossi A., et al. “The impact of physical activity on mortality in patients with high blood pressure: a systematic review”. Journal of Hypertens7 (2012): 1277-1288.
7. Lim SS., et al. “A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet9859 (2012): 2224-2260.
8. Clinical guidelines. “Diagnosis and treatment of arterial hypertension”. Systemic Hypertension1 (2019): 6-31.
9. Wald DS., et al. “Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials”. The American Journal of Medicine3 (2009): 290-300.
10. Kim S., et al. “Medication Adherence and the Risk of Cardiovascular Mortality and Hospitalization Among Patients With Newly Prescribed Antihypertensive Medications”. Hypertension3 (2016): 506-512.

Citation

Citation: VI Kupaev., et al. “Analysis of the Controlled Essential Hypertension’s Pharmacotherapy in General Doctor in Russian Federation (Pharmacoepidemiological Analysis)”.Acta Scientific Medical Sciences 6.6 (2022): 155-159.

Copyright

Copyright: © 2022 VI Kupaev., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.